Citius Pharmaceuticals Inc. (NASDAQ: CTXR)
$0.84
+0.0706 ( +9.22% ) 3.2M
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma . Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome.
Market Data
Open
$0.84
Previous close
$0.77
Volume
3.2M
Market cap
$153.57M
Day range
$0.76 - $0.87
52 week range
$0.48 - $1.27
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 15 | May 21, 2024 |
10-q | Quarterly Reports | 55 | May 14, 2024 |
8-k | 8K-related | 15 | May 14, 2024 |
8-k | 8K-related | 18 | Apr 30, 2024 |
8-k | 8K-related | 13 | Apr 05, 2024 |
4 | Insider transactions | 1 | Apr 05, 2024 |
4 | Insider transactions | 1 | Apr 05, 2024 |
3 | Insider transactions | 2 | Mar 18, 2024 |
8-k | 8K-related | 15 | Mar 18, 2024 |
4 | Insider transactions | 1 | Mar 18, 2024 |